Sofosbuvir/Velpatasvir

索磷布韦/维帕他韦

Report date: 2026/04/30 20:00:20

Base Information

Drug NameSofosbuvir/Velpatasvir
Drug Alias NameVelpatasvir/Sofosbuvir索菲布韦/维帕他韦Sofosbuvir and Velpatasvir维帕他韦/索菲布韦Sofosbuvir•Velpatasvir +[14] 
ClassificationSmall molecules
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsNonstructural protein 5A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5A
Therapy Area/IndicationsRejection of renal transplantationHeart FailureKidney Failure, Chronic +[6] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2016/06/28
Country/TerritoryBelgiumArmeniaCanada +[26] 
CombinationsYes VelpatasvirSofosbuvir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pittsburgh Medical CenterBurnet InstituteHannover Medical School +[9] 
Inactive CompaniesKirby InstituteThe Ohio State UniversityHong Kong Gillian Science Co Ltd Beijing Representative Office
Active IndicationsRejection of renal transplantationHeart FailureKidney Failure, Chronic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeJ05AP55
Related LinksWikipediaKEGG